Monica Beam, PhD   SVP, Alexandria Venture Investments

Dr. Beam has led venture capital investments in more than 25 life science and technology companies in the areas of therapeutics, enabling technologies, and diagnostics and also supports a number of strategic corporate initiatives. She supports Alexandria’s west coast operations by providing scientific expertise and insights on the life science and technology sectors. She is responsible for venture investment, business development, and tenant underwriting in Alexandria’s San Francisco Bay Area and Seattle cluster locations through the company’s strategic venture investment arm, Alexandria Venture Investments.  Dr. Beam represents Alexandria as a Board Observer for DiCE Molecules, BioGraph 55, and TwinStrand Biosciences.

Prior to joining Alexandria, Dr. Beam was Vice President at Square 1 Bank, where she worked closely with early-stage, venture-backed life science and technology companies and venture capitalists to structure, underwrite, and monitor debt transactions. She earned her Doctor of Philosophy degree in Biomedical Engineering from Northwestern University and her Bachelor of Science degree in Chemical Engineering from Stanford University. Dr. Beam’s research and publications have focused on the fields of protein misfolding, neurodegenerative disease, biochemistry, and florescence-based imaging techniques.

BILL BURKOTH   Executive Director, Pfizer Ventures

Since joining Pfizer Ventures, the venture capital arm of Pfizer Inc., in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently also serves on the board of directors of NeuMoDx Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Bill received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

Mark Gallop, PhD   Executive-in-Residence, 5AM

Mark Gallop joined 5AM Ventures as an Executive-in-Residence in June 2018, and consults with emerging biotechnology companies on drug discovery technologies and strategies, with an emphasis on neuroscience, oncology, gastrointestinal disorders and prodrug design.

From 2012 to 2017 he served as the founding Chief Scientific Officer at Nurix, Inc., a venture-backed discovery company formed to explore drug development targeting ubiquitin ligase enzymes, with therapeutic applications spanning oncology, immunology, inflammation and immuno-oncology. Prior to joining Nurix, he was Senior Vice President of Research and XenoPort, Inc., a company he co-founded in 1999 with the mission of improving the clinical utility of medicines by exploiting active transport mechanisms to optimize pharmacokinetic properties of drugs. While at XenoPort, his team discovered Horizant™, a prodrug of gabapentin that was approved by the FDA in 2011 and the MHW in Japan in 2012 for the treatment of restless legs syndrome and neuropathic pain. Previously, Dr. Gallop was Senior Director of Combinatorial Chemistry at Affymax.

He is recognized as an early pioneer and international expert in solid-phase combinatorial chemistry and was a recipient of the ACROS award of the Belgian Organic Synthesis Symposium in 1996 for his outstanding contributions to this field. He is an inventor on more than 100 issued or pending U.S., and PCT patents and an author of over 60 manuscripts in peer-reviewed journals. In 1994, he co-authored a landmark review of the then-emerging field of combinatorial chemistry that has subsequently become one of the most highly cited papers in chemistry.

After undergraduate studies in New Zealand, he obtained his Ph.D. degrees in inorganic chemistry from the University of Cambridge and was a Lindemann postdoctoral fellow in the laboratories of Profs. Peter G. Schultz and Robert G. Bergman at the University of California, Berkeley.

Mitchell Mutz, PhD   Investment Director, Roche Venture Fund

Mitchell Mutz, PhD, is an  Investment Director at the Roche Venture Fund.  He joined Roche in 2017, bringing a broad depth of experience as founder, President, and Chief Scientific Officer of Amplyx Pharmaceuticals, a clinical stage therapeutics company that is currently developing APX001, a novel, broad spectrum antifungal compound.  Amplyx has attracted over $130M in venture and grant financing.  At Amplyx, he identified, led negotiations, and successfully in-licensed APX001 from Eisai.  Mitchell has also authored or co-authored 15 funded NIH grant proposals, garnering over $15M in non-dilutive funding.  He is also an inventor on 32 issued patents.

Previously, Mitchell was the first employee and Principal Scientist at Labcyte Inc., Sunnyvale, CA, a tools company that uses acoustic beams to achieve precise, non-contact transfer of liquid without the use of pipet tips.  Labcyte has received widespread industry recognition including selection by the World Economic Forum as a 2015 Technology Pioneer, has over 220 employees worldwide, and has seen their technology adopted by all top ten large pharmaceutical companies and a host of smaller biotechnology companies, universities, and research institutes.  Prior to Labcyte, he was a research scientist at Scios which was later acquired by Johnson and Johnson.  In addition to Biodesy, Mitchell currently serves on the boards of Pandion Therapeutics, Purigen Biosytems and Fabric Genomics, and was previously on the board of Amplyx.

Dr. Mutz received his PhD in Chemistry from the University of Rochester, NY, his Diploma in Orchestral Studies from the University of London, England, and a BA in Chemistry from Oberlin College.

Ariel Notcovich   CEO

Ariel G. Notcovich is an accomplished life science executive, with a wide experience in all aspects and stages of product development for life science markets, having worked in startup as well as in corporate environments. Ariel founded ProteOptics during his graduate studies in Physics at the Technion-Israel Institute of Technology and served as its CTO and CEO. The company developed a multichannel Surface Plasmon Resonance imaging system for the label-free analysis of molecular interactions. ProteOptics was acquired by Bio-Rad Laboratories. Ariel successfully managed the integration, establishing his team as the innovation center for Bio-Rad Life Sciences Group. As a visionary and entrepreneurial leader of Bio-Rad R&D, he created the Protein Technologies R&D group to develop innovative products for life sciences markets. Products developed in Ariel’s group included systems, instrumentation, software, consumables and reagents for imaging, chromatography, gel electrophoresis and blotting, protein interactions and other product lines.

ANDREW J. SCHWAB   Managing Partner, 5AM Ventures

Prior to founding 5AM in 2002, Andrew was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Andrew was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (IPO), Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team.


Joe Victor brings more than 30 years of experience fostering product innovation and building value for customers, shareholders, and employees. Most recently, he was CEO of privately held DVS Sciences, a designer and manufacturer of a transformational bioanalytical platform including high-end mass cytometry instruments and associated consumables. DVS was sold in early 2014 to Fluidigm, Inc., a leading Life Sciences publicly held company.  Prior to DVS, Mr. Victor was CEO of Applied Precision Inc., a manufacturer of high performance microscopy systems for life sciences research and drug development acquired by GE Healthcare in 2011. Before that he drove significant sales growth, new product development and overall profitability of the Applied Precision business in the roles of President, Sr. VP Life Sciences, VP R&D / Operations, and VP R&D. Prior to Applied Precision, Mr. Victor held various executive management and technical positions in the high technology, aviation, and energy markets.  Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington. Mr. Victor is based in the Seattle area and currently serves on the following company board of directors:  Biodesy, Glencoe Software, Precision Nanosystems, Purigen, and RareCyte.  Mr Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation.


Andrej Sali, PhD  

Andrej Sali received his BSc degree in chemistry from the University of Ljubljana, Slovenia, in 1987; and his PhD from Birkbeck College, University of London, UK, in 1991, under the supervision of Professor Tom L. Blundell, where he developed the MODELLER program for comparative modeling of protein structures. He was then a postdoc with Professor Martin Karplus at Harvard University as a Jane Coffin Childs Memorial Fund fellow, studying lattice Monte Carlo models of protein folding. From 1995 to 2002, he was first an Assistant Professor and then an Associate Professor at The Rockefeller University. In 2003, he moved to University of California, San Francisco, as a Professor of Computational Biology in the Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, and California Institute for Quantitative Biosciences (QB3). He was a Sinsheimer Scholar (1996), an Alfred P. Sloan Research Fellow (1998), an Irma T. Hirschl Trust Career Scientist (2000), the recipient of the Zois Award of Science Ambassador of Republic of Slovenia (2007), and elected a Fellow of International Society for Computational Biology (2014). He has been an Editor of Structure since 2002. He is also a Founder of Prospect Genomix that merged with Structural Genomix (2001); and of Global Blood Therapeutics (2012). Dr. Sali develops and applies computational methods for determining and modulating structures and functions of proteins and their assemblies.

Richard Ulevitch, PhD  

Richard J. Ulevitch, Ph.D. joined 5AM Ventures in 2002 as an Advisor and then Chairman of 5AM Strategic Advisory Board before transitioning to a Venture Partner role in 2008. Previously he was Chairman of 5AM’s Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute in La Jolla, California where he remains as Professor and Chairman Emeritus. For nearly four decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He serves as a scientific advisor to Aravis Ventures, a European life science venture capital fund and previously served as an advisor to the Lombard Odier Immunology Fund, where he evaluated numerous biotechnology companies over a fifteen-year span. Dr. Ulevitch serves or has served on the Scientific Advisory Boards of Arvinas, Biodesy, Bird Rock Bio, Cidara (NASDAQ: CDTX), Cleave, Envoy (acquired by Takeda), Ideaya, Igenica, Ikaria (acquired by Mallinckrodt), Pulmatrix (NASDAQ: PULM) as well as on the Board of PhaseRx. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a Ph.D. in Biochemistry from the University of Pennsylvania. Dr. Ulevitch is based in the San Francisco, CA office.

Erica Ollmann Saphire, PhD  

Erica Ollmann Saphire, Ph.D. is a Professor of Immunology and Microbial Science at The Scripps Research Institute. Her research combines structural biology with cellular virology and immunology to understand and defeat viral pathogens. Her team has revealed the structures of the trimeric, prefusion glycoproteins for the Ebola, Lassa, Sudan and Marburg viruses, revealed neutralizing and non-neutralizing antibody epitopes, how these viruses drive themselves into cells, how they suppress immune function, and where the viruses are vulnerable. Her team solved the only structure of the entire human antibody itself and made the groundbreaking discovery that expanded a central dogma of molecular biology: certain proteins of these viruses rearrange their 3D structures to achieve different functions at different stages of their life cycle. She is the founder and Director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium, a 43+ laboratory, 5-continent basic and translational research effort.  This organization, the VIC, united the field into a single force to understand and provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Her work has been recognized at the White House with a Presidential Early Career Award, by the Burroughs Wellcome Fund, by young investigator awards from ASBMB, ASM and the International Society for Antiviral Research, and by the Surhain Sidhu award for the most outstanding contribution to the field of diffraction. She is a Fellow of AAM and AAAS, and serves on the Scientific Leadership Boards of the Global Virus Network and the Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Frank McCormick, PhD  

Frank McCormick, PhD, FRS, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick’s current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.

Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr.  McCormick is the author of over 320 scientific publications and holds more than 20 issued patents. He was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014. He also served as President, 2012-2013, for the American Association for Cancer Research (AACR). Since 2013 he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

Theodore Jardetzky, PhD  

Theodore (Ted) Jardetzky is a Professor in the Department of Structural Biology in the Stanford School of Medicine where he is affiliated with the Programs in Biophysics and Immunology and a fellow of the Stanford Chem-H Institute. Professor Jardetzky’s research focuses on understanding mechanisms of virus entry and neutralization, as well as the allergic response mediated by IgE antibodies. Professor Jardetzky has made seminal contributions to understanding how the recognition of host receptors by viral glycoproteins initiates cell-specific entry of herpesviruses and paramyxoviruses, providing mechanistic insight into antibody-mediated neutralization and targets for subunit vaccine development.  His research has clarified how IgE antibodies interact with high affinity cellular receptors that trigger inflammatory responses associated with food allergies and asthma. His laboratory has discovered novel ‘disruptive’ inhibitors targeting this IgE receptor interaction that rapidly dissociate IgE complexes, demonstrating the potential for the discovery of a novel and more potent class of anti-allergy therapeutics. Professor Jardetzky’s research is funded by the National Institutes of Health and the Department of Defense and has been recognized by the awarding of an NIH MERIT award and his selection as a Pew Scholar in the Biomedical Sciences, a Scholar of the Leukemia and Lymphoma Society, an Investigator of the Cancer Research Institute, a Fellow of the American Academy for Microbiology and a Fellow of the American Association for the Advancement of Science.


Josh is the Founder of Biodesy and the inventor of the Second Harmonic Generation (SHG) technique for studying biological molecules. Josh was awarded a number of NSF and NIH grants and obtained key scientific breakthroughs that galvanized the scientific and venture capital communities.  Previously, Josh was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. His expertise and interests are in the areas of Biophysics and Physical Chemistry. Josh received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis which converts light into chemical energy.